{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:04:28Z","timestamp":1791295468646,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s40257-016-0184-6","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T15:36:51Z","timestamp":1458315411000},"page":"179-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Afamelanotide: A Review in Erythropoietic Protoporphyria"],"prefix":"10.1007","volume":"17","author":[{"given":"Esther S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karly P.","family":"Garnock-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"key":"184_CR1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1172-4-19","volume":"4","author":"M Lecha","year":"2009","unstructured":"Lecha M, Puy H, Deybach J-C. Erythropoietic protoporphyria. Orphanet J Rare Dis. 2009;4:19.","journal-title":"Orphanet J Rare Dis."},{"key":"184_CR2","volume-title":"GeneReviews\u00ae","author":"M Balwani","year":"2014","unstructured":"Balwani M, Bloomer J, Desnick R, et al. Erythropoietic protoporphyria, autosomal recessive. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews\u00ae. Seattle: University of Washington; 2014."},{"key":"184_CR3","unstructured":"European Medicines Agency. Scenesse: EU public assessment report. 2014. http:\/\/www.ema.europa.eu . Accessed 16 Feb 2016."},{"key":"184_CR4","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/978-3-662-45139-7_79","volume-title":"European handbook of dermatological treatments","author":"RPE Sarkany","year":"2015","unstructured":"Sarkany RPE. The cutaneous porphyrias. In: Katsambas AD, Lotti TM, Dessinioti C, et al., editors. European handbook of dermatological treatments. Berlin: Springer; 2015. p. 763\u201380."},{"key":"184_CR5","unstructured":"British Association of Dermatologists. Erythropoietic protoporphyria and X-linked dominant protoporphyria. 2014. http:\/\/www.bad.org.uk . Accessed 16 Feb 2016."},{"key":"184_CR6","unstructured":"Poh-Fitzpatrick MB. Protoporphyria: background. 2014. http:\/\/emedicine.medscape.com . Accessed 16 Feb 2016."},{"key":"184_CR7","volume-title":"GeneReviews\u00ae","author":"M Balwani","year":"2013","unstructured":"Balwani M, Bloomer J, Desnick R. X-linked protoporphyria. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews\u00ae. Seattle: University of Washington; 2013."},{"issue":"1","key":"184_CR8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cphy.c120006","volume":"3","author":"HL Bonkovsky","year":"2013","unstructured":"Bonkovsky HL, Guo JT, Hou W, et al. Porphyrin and heme metabolism and the porphyrias. Compr Physiol. 2013;3(1):365\u2013401.","journal-title":"Compr Physiol."},{"issue":"3","key":"184_CR9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2796.2010.02236.x","volume":"269","author":"S Wahlin","year":"2011","unstructured":"Wahlin S, Floderus Y, St\u00e5l P, et al. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med. 2011;269(3):278\u201388.","journal-title":"J Intern Med."},{"issue":"3","key":"184_CR10","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2133.2006.07472.x","volume":"155","author":"SA Holme","year":"2006","unstructured":"Holme SA, Anstey AV, Finlay AY, et al. Erythropoietic protoporphyria in the UK: clinical features and effect on quality of life. Br J Dermatol. 2006;155(3):574\u201381.","journal-title":"Br J Dermatol."},{"issue":"1","key":"184_CR11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/17512433.2014.956089","volume":"8","author":"EI Minder","year":"2015","unstructured":"Minder EI, Schneider-Yin X. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert Rev Clin Pharmacol. 2015;8(1):43\u201353.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"184_CR12","unstructured":"European Medicines Agency. Scenesse (afamelanotide) implant: EU summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 16 Feb 2016."},{"issue":"3","key":"184_CR13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1006\/bbrc.1994.2581","volume":"204","author":"C Haskell-Luevano","year":"1994","unstructured":"Haskell-Luevano C, Miwa H, Dickinson C, et al. Binding and cAMP studies of melanotropin peptides with the cloned human peripheral melanocortin receptor, hMC1R. Biochem Biophys Res Commun. 1994;204(3):1137\u201342.","journal-title":"Biochem Biophys Res Commun."},{"issue":"2","key":"184_CR14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1751-1097.2008.00294.x","volume":"84","author":"ZA Abdel-Malek","year":"2008","unstructured":"Abdel-Malek ZA, Knittel J, Kadekaro AL, et al. The melanocortin 1 receptor and the UV response of human melanocytes: a shift in paradigm. Photochem Photobiol. 2008;84(2):501\u20138.","journal-title":"Photochem Photobiol."},{"issue":"8","key":"184_CR15","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.jid.5700317","volume":"126","author":"RS Barnetson","year":"2006","unstructured":"Barnetson RS, Ooi TK, Zhuang L, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006;126(8):1869\u201378.","journal-title":"J Invest Dermatol."},{"issue":"4","key":"184_CR16","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1562\/0031-8655(2000)072<0526:IEEATI>2.0.CO;2","volume":"72","author":"RT Dorr","year":"2000","unstructured":"Dorr RT, Dvorakova K, Brooks C, et al. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol. 2000;72(4):526\u201332.","journal-title":"Photochem Photobiol."},{"issue":"6","key":"184_CR17","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1751-1097.2009.00595.x","volume":"85","author":"JH Harms","year":"2009","unstructured":"Harms JH, Lautenschlager S, Minder CE, et al. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol. 2009;85(6):1434\u20139.","journal-title":"Photochem Photobiol."},{"issue":"5","key":"184_CR18","first-page":"1143","volume":"164","author":"G Biolcati","year":"2011","unstructured":"Biolcati G, Deybach J-C, Hanneken S, et al. A randomized phase III trial of afamelanotide (Scenesse\u00ae), an agonistic \u03b1-melanocyte stimulating hormone analogue in the treatment of protoporphyria-induced phototoxicity [abstract no. O27]. Br J Dermatol. 2011;164(5):1143.","journal-title":"Br J Dermatol."},{"key":"184_CR19","unstructured":"Clinuvel. Clinuvel reports positive results in phase III porphyria (EPP) clinical trial [media release]. 2010. http:\/\/www.clinuvel.com ."},{"issue":"1","key":"184_CR20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","volume":"373","author":"JG Langendonk","year":"2015","unstructured":"Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48\u201359.","journal-title":"N Engl J Med."},{"issue":"5","key":"184_CR21","first-page":"1169","volume":"164","author":"C Kochs","year":"2011","unstructured":"Kochs C, Muehlenstaedt E, Siegesmund M, et al. The clinical spectrum of cutaneous effects of the synthetic \u03b1-melanocyte stimulating hormone analogue afamelanotide [abstract no. P49]. Br J Dermatol. 2011;164(5):1169.","journal-title":"Br J Dermatol."},{"key":"184_CR22","unstructured":"Clinuvel. Clinuvel demonstrates positive treatment effect of afamelanotide in US phase II study [media release]. 2011. http:\/\/www.clinuvel.com ."},{"key":"184_CR23","unstructured":"Clinuvel. Completed EPP trials. 2014. http:\/\/www.clinuvel.com\/en\/scenesse\/completed-epp-trials . Accessed 16 Feb 2016."},{"issue":"6","key":"184_CR24","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/bjd.13598","volume":"172","author":"G Biolcati","year":"2015","unstructured":"Biolcati G, Marchesini E, Sorge F, et al. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601\u201312.","journal-title":"Br J Dermatol."},{"issue":"2","key":"184_CR25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000362174","volume":"28","author":"S Lengweiler","year":"2015","unstructured":"Lengweiler S, Kreim S, Barman-Aks\u00f6zen J, et al. Evaluation of the immunogenicity of the synthetic \u03b1-melanocyte-stimulating hormone (\u03b1-MSH) analogue afamelanotide ([Nle4-D-Phe7]-\u03b1-MSH, Scenesse\u00ae) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-\u03b1-MSH antibodies. Skin Pharmacol Physiol. 2015;28(2):103\u201313.","journal-title":"Skin Pharmacol Physiol."},{"key":"184_CR26","unstructured":"US FDA. Orphan drug designations and approvals: afamelanotide. 2008. http:\/\/www.fda.gov . Accessed 16 Feb 2016."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0184-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-016-0184-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-016-0184-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T11:49:45Z","timestamp":1655293785000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-016-0184-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["184"],"URL":"https:\/\/doi.org\/10.1007\/s40257-016-0184-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]}}}